A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma

Phase 4

Recruiting

• Conditions: Bladder Urothelial Carcinoma
• Interventions: Drug: Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)

• Registration Number: NCT05220124
• Lead Sponsor: Tianjin Medical University Second Hospital

Brief Summary

A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.

Detailed Description

To evaluate the progression free survival of intestinal probiotics in immunotherapy for urothelial carcinoma. Changes in fecal flora abundance before and after treatment were assessed to identify subjects most likely to benefit from enteric probiotics treatment.

Study Timeline

• Study Start: 2022-01-05
• Study First Submitted: 2022-01-14
• Status Verified: 2022-02
• Study First Submitted QC: 2022-02-01
• Last Update Submitted: 2022-02-01
• Study First Posted: 2022-02-02
• Last Update Posted: 2022-02-02
• Primary Completion: 2024-11-30
• Study Completion: 2024-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 190

Inclusion Criteria

1. Patients diagnosed with urothelial carcinoma and undergoing immunotherapy ;

2. Age ≥ 18 years;

3. Expected survival time is greater than 12 weeks;

4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 1 or 2;

5. Organ function level must meet the following requirements:

   Hematological indexes: neutrophil count >= 1.5x10^9/L, platelet count >= 100x10^9/L, hemoglobin >= 9.0 g/dl (can be maintained by symptomatic treatment); Liver function: total bilirubin <=1.5 ULN, alanine aminotransferase and aspartate aminotransferase <=2.5 ULN (can be maintained by symptomatic treatment);

6. The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up;

7. Willing and able to provide written informed consent.

Exclusion Criteria

1. Receive live attenuated vaccine within 4 weeks before treatment or during the study period;
2. Active, known or suspected autoimmune diseases;
3. Cannot take orally or are allergic to probiotics ;
4. History of primary immunodeficiency ;
5. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
6. Pregnant or lactating female patients;
7. Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions;
8. Uncontrolled concurrent diseases, including but not limited to:

HIV infected (HIV antibody positive); Severe infection in active stage or poorly controlled; Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [hypertension greater than or equal to conmon terminology criteria for adverse events （CTCAE） grade 2 after drug treatment]); Patients with active bleeding or new thrombotic disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Immunotherapy with Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)	Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)	420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 3-4 treatment cycles,21 days per cycle.

Primary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	up to 3 years	Time from randomness to the first occurrence of disease progression or death from any cause.

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DOR)	up to 3 years	The time from the first judgment of complete response (CR) or partial response (PR) to the discovery of progressive disease （PD）.
Overall Survival (OS)	up to 3 years	Defined as the number of days from study entry to death. Individuals who are alive at last contact will be censored on the date of last contact.
Serious Adverse Event (SAE)	up to 3 years	The adverse events that occurred in the study were difficult to manage.
Overall response rate (ORR)	up to 3 years	defined as the proportion of patients who have a partial or complete response to therapy.
Disease control rate (DCR)	up to 3 years	The percentage of cases with remission and lesion stability after treatment in the number of evaluable cases.

Trial Locations

Locations (1)

Tianjin Medical University Second Hospital; 🇨🇳 Tianjin, Tianjin, China